Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Purchased by Northern Trust Corp

Northern Trust Corp lifted its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 7.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 734,847 shares of the company’s stock after acquiring an additional 52,464 shares during the period. Northern Trust Corp owned 0.45% of Neumora Therapeutics worth $7,789,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Capital International Investors boosted its stake in Neumora Therapeutics by 692.1% during the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company’s stock worth $39,224,000 after buying an additional 3,233,179 shares during the last quarter. Vanguard Group Inc. boosted its stake in Neumora Therapeutics by 4.5% during the fourth quarter. Vanguard Group Inc. now owns 4,572,308 shares of the company’s stock worth $48,466,000 after buying an additional 195,142 shares during the last quarter. Rock Springs Capital Management LP boosted its stake in Neumora Therapeutics by 15.3% during the fourth quarter. Rock Springs Capital Management LP now owns 955,106 shares of the company’s stock worth $10,124,000 after buying an additional 127,005 shares during the last quarter. Swiss National Bank acquired a new position in Neumora Therapeutics during the fourth quarter worth $1,168,000. Finally, Norges Bank acquired a new position in Neumora Therapeutics during the fourth quarter worth $1,166,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Stock Up 5.1%

NASDAQ:NMRA opened at $0.70 on Monday. The company has a market capitalization of $113.22 million, a P/E ratio of -0.37 and a beta of 2.96. Neumora Therapeutics, Inc. has a 52 week low of $0.61 and a 52 week high of $17.19. The stock’s fifty day moving average is $0.85 and its two-hundred day moving average is $4.24.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02). Sell-side analysts anticipate that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on NMRA shares. Needham & Company LLC reissued a “buy” rating and set a $5.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, May 13th. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Guggenheim lowered Neumora Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, March 7th. Bank of America restated an “underperform” rating and issued a $1.00 target price (down previously from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. Finally, HC Wainwright reduced their target price on Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Neumora Therapeutics has a consensus rating of “Hold” and a consensus price target of $9.29.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.